SCHEMBL21807162

SCHEMBL21807162

COC(=O)Cc1ccc(OC)c(C2CC2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
GAA P10253 4/20 0.47
GFER P55789 1/20 0.47
PTGDR Q13258 1/20 0.46
PTGDR2 Q9Y5Y4 1/20 0.46
ABL1 P00519 1/20 0.45
RIN1 Q13671 1/20 0.45
SELL P14151 1/20 0.44
SELP P16109 1/20 0.44
TSHR P16473 1/20 0.44
NFKB1 P19838 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
MAPT P10636 3/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C19 P33261 1/20 0.44
CYP4F2 P78329 1/20 0.44
CYP4A11 Q02928 1/20 0.44
EPHX2 P34913 1/20 0.44
SIGMAR1 Q99720 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29626821 0.82 ALDH1A1 (0.62) ALDH1A1GAAGFERABL1RIN1
SCHEMBL198282 0.82 ALDH1A1 (0.62) ALDH1A1GAAGFERABL1RIN1
SCHEMBL8574560 0.81 GAA (0.57) ALDH1A1GAAPTGDRPTGDR2SELL
SCHEMBL4183281 0.81 GAA (0.55) ALDH1A1GAAGFERPTGDRPTGDR2
SCHEMBL7792682 0.80 PTGDR2 (0.57) ALDH1A1GAAPTGDRPTGDR2SELL
SCHEMBL31284885 0.80 GAA (0.44) ALDH1A1GAAGFERPTGDRPTGDR2
SCHEMBL16961640 0.80 ALDH1A1 (0.47) ALDH1A1MAPTSIGMAR1HTTNPC1
SCHEMBL8432177 0.79 PTGDR2 (0.46) PTGDRPTGDR2L3MBTL1SMN1; SMN2
SCHEMBL7332617 0.79 PDE4B (0.58)
SCHEMBL6366896 0.79 RECQL (0.60)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. 2023-03-02 US disclosed
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. 2023-03-02 US disclosed
EP-3852790-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X Forma Therapeutics, Inc. (US) 2021-07-28 EP disclosed
CN-113164571-A Inhibition of ubiquitin-specific peptidase 9X 福马治疗股份有限公司 2021-07-23 CN disclosed
WO-2020061261-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. (US) 2020-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X USP9X, USP19, USP39 ALDH1A1 1794/4885GAA 326/4885GFER 3574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.